tailieunhanh - Báo cáo y học: " One-year treatment with mometasone furoate in chronic obstructive pulmonary disease"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. | Respiratory Research BioMed Zentral Research Open Access One-year treatment with mometasone furoate in chronic obstructive pulmonary disease Peter MA Calverley 1 Stephen Rennard2 Harold S Nelson3 Jill P Karpel4 Eduardo H Abbate5 Paul Stryszak6 and Heribert Staudinger6 Address Department of Medicine University Hospital Aintree Liverpool UK 2University of Nebraska Medical Center Omaha NE USA 3Department of Medicine National Jewish Medical and Research Center Denver CO USA 4North Shore University Hospital New Hyde Park NY USA 5Asociacion Argentina de Medicina Respiratoria Buenos Aires Argentina and 6Schering-Plough Research Institute Kenilworth NJ USA E-mail Peter MA Calverley - pmacal@ Stephen Rennard - srennard@ Harold S Nelson - nelsonh@ Jill P Karpel - jpkarpel@ Eduardo H Abbate - edu1001@ Paul Stryszak - Heribert Staudinger - Corresponding author Published 13 November 2008 Received 23 May 2008 Respiratory Research 2008 9 73 doi I465-992I-9-73 Accepted 13 November 2008 This article is available from http content 9 I 73 2008 Calverley et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Many patients with chronic obstructive pulmonary disease COPD are treated with twice daily BID inhaled corticosteroids ICS . This study evaluated whether daily PM mometasone furoate administered via a dry powder inhaler MF-DPI was equally effective compared to twice daily dosing. In a 52-week randomized double-blind placebo-controlled study 9II subjects with moderate-to-severe COPD managed without ICS received MF-DPI 800 pg Qd pm Mf-DPI 400 pg BID or placebo. The change from baseline in .